 Connection
Michael Bristow to Cardiac Output, Low
This is a "connection" page, showing publications Michael Bristow has written about Cardiac Output, Low.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.388 |
|
|
|
-
Bristow MR. Cardiac resynchronization therapy and adrenergic mechanisms. Am J Physiol Heart Circ Physiol. 2006 Dec; 291(6):H2590-1.
Score: 0.260
-
Carson P, Anand I, O'Connor C, Jaski B, Steinberg J, Lwin A, Lindenfeld J, Ghali J, Ghali J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005 Dec 20; 46(12):2329-34.
Score: 0.249
-
Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005 Sep; 2(9):475-83.
Score: 0.244
-
Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998 Aug; 352 Suppl 1:SI8-14.
Score: 0.149
-
Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
Score: 0.137
-
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
Score: 0.133
-
Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 01; 94(11):2817-25.
Score: 0.133
-
Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
Score: 0.124
-
Jaggers J, Fullerton DA, Campbell DN, Andrea B, Jones SD, Brown JM, Wolfel EE, Lindenfeld J, Grover FL, Bristow MR. Cardiac allograft failure: successful use of biventricular assist device. Ann Thorac Surg. 1995 Nov; 60(5):1409-11.
Score: 0.123
-
Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993 Mar 25; 71(9):12C-22C.
Score: 0.103
-
Anderson FL, Port JD, Reid BB, Larrabee P, Hanson G, Bristow MR. Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta-adrenergic receptor downregulation. Circulation. 1992 Jan; 85(1):46-53.
Score: 0.095
-
Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation. 1991 Jun; 83(6):1866-72.
Score: 0.091
-
Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990 Aug; 82(2 Suppl):I12-25.
Score: 0.086
-
Hershberger RE, Anderson FL, Bristow MR. Vasoactive intestinal peptide receptor in failing human ventricular myocardium exhibits increased affinity and decreased density. Circ Res. 1989 Aug; 65(2):283-94.
Score: 0.080
-
Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar; 35(3):295-303.
Score: 0.078
-
Bristow MR, Lee HE, Gilbert EM, Renlund DG, Hegewald MG, Hershberger RE, O'Connell JB. Use of enoximone in patients awaiting cardiac transplant. Br J Clin Pract Suppl. 1988 Dec; 64:69-72.
Score: 0.076
-
Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker TM, Gunderman MR. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005 Dec 20; 46(12):2311-21.
Score: 0.062
-
Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003 Oct 07; 108(14):1707-12.
Score: 0.053
-
Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res. 2000 Mar 03; 86(4):386-90.
Score: 0.042
-
Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
Score: 0.033
-
Cleland JG, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J. 1996 Nov; 17(11):1629-39.
Score: 0.033
-
Movsesian MA, Bristow MR, Krall J. Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res. 1989 Oct; 65(4):1141-4.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|